These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11847486)

  • 1. Elevated levels of serum prolactin in patients with advanced multiple myeloma.
    Gadó K; Rimanóczi E; Hasitz A; Gigler G; Tóth BE; Nagy GM; Pálóczi K; Domján G
    Neuroimmunomodulation; 2001; 9(4):231-6. PubMed ID: 11847486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum levels of cyclo (His-Pro), an endogenous inhibitor of pituitary prolactin secretion, in systemic lupus erythematosus patients.
    Jara LJ; Prasad C; Espinoza LR
    Lupus; 1997; 6(3):258-60. PubMed ID: 9104733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
    Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
    Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients.
    Gadó K; Nagy G; Hasitz A; Tóth BE; Rimanóczi E; Domján G
    Neuroimmunomodulation; 2001; 9(2):95-102. PubMed ID: 11549891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
    D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
    AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
    Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
    Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of interleukin-22 in multiple myeloma.
    Tsirakis G; Pappa CA; Kolovou A; Kokonozaki M; Neonakis I; Alexandrakis MG
    Hematology; 2015 Apr; 20(3):143-7. PubMed ID: 25055724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma.
    Tsirakis G; Pappa CA; Kanellou P; Stratinaki MA; Xekalou A; Psarakis FE; Sakellaris G; Alegakis A; Stathopoulos EN; Alexandrakis MG
    Hematol Oncol; 2012 Sep; 30(3):131-6. PubMed ID: 21919032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.
    Mathiot C; Teillaud JL; Elmalek M; Mosseri V; Euller-Ziegler L; Daragon A; Grosbois B; Michaux JL; Facon T; Bernard JF
    J Clin Immunol; 1993 Jan; 13(1):41-8. PubMed ID: 8445043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease].
    Scudla V; Bacovský J; Budíková M; Klímová D; Faltýnek L
    Vnitr Lek; 1995 Sep; 41(9):593-8. PubMed ID: 7483349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma.
    Jurisić V; Colović M
    Med Oncol; 2002; 19(3):133-9. PubMed ID: 12482123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
    Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic implications of myeloma staging.
    Durie BG; Bataille R
    Eur J Haematol Suppl; 1989; 51():111-6. PubMed ID: 2697583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
    Scudla V; Vavrdová V; Budíková M; Indrák K
    Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis.
    Mehtap O; Atesoglu EB; Tarkun P; Hacihanefioglu A; Dolasik I; Musul MM
    J Postgrad Med; 2014; 60(2):141-4. PubMed ID: 24823512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-2-microglobulin in multiple myeloma.
    Musarurwa C; Matarira HT
    Cent Afr J Med; 2004; 50(1-2):19-20. PubMed ID: 15490720
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
    Kraj M; Maj S; Pogłód R; Rostkowska J
    Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
    Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
    Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma: an immunoclinical study of disease and response to treatment.
    Thavasu PW; Ganjoo RK; Maidment SA; Love SB; Williams AH; Malplas JS; Balkwill FR
    Hematol Oncol; 1995; 13(2):69-82. PubMed ID: 7797195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.